{"id":"W4247541485","doi":"10.1200/jco.2013.31.15_suppl.8028","title":"Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in <i>KRAS</i>-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Trametinib; Medicine; KRAS; Internal medicine; Tolerability; Oncology; Lung cancer; Docetaxel; Neutropenia; Mucositis; MEK inhibitor; Adverse effect; Cancer; Chemotherapy; Colorectal cancer; MAPK/ERK pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000720181,0.0009851932,0.001263281,0.0003664718,0.0002533614,0.0008789481,0.0006978169,0.0007581977,0.002877979],"category_scores_gemma":[0.0004288392,0.0005506507,0.0008535523,0.0004187123,0.00050573,0.0006312558,0.0002759776,0.00189295,0.0008166961],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008651183,"about_ca_system_score_gemma":0.00117868,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001221658,"about_ca_topic_score_gemma":0.004794748,"domain_scores_codex":[0.9997937,0.00008290278,0.00001785725,0.00003625345,0.00002296921,0.00004625399],"domain_scores_gemma":[0.9997215,0.00003960788,0.00006495565,0.00001732566,0.00001541955,0.0001412215],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7658675,0.03781244,0.008827862,0.001483892,0.001616703,0.0002810448,0.0002424661,0.002591161,0.04342709,0.0002193273,0.003850573,0.13378],"study_design_scores_gemma":[0.5895166,0.3827985,0.01708166,0.00007156959,0.000825638,0.0004929606,0.0000713164,0.001401753,0.004714005,0.0001092682,0.002878472,0.00003815909],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938256,0.002175401,0.0001871,0.0002113809,0.00005825295,0.001163502,0.0006715327,0.00007689001,0.001630445],"genre_scores_gemma":[0.9933202,0.001898163,0.0005622088,0.000272065,0.00007572024,0.0007969392,0.001334775,0.00001524018,0.001724765],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002877979,"threshold_uncertainty_score":0.009627819,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04455802113006916,"score_gpt":0.4607209968679737,"score_spread":0.4161629757379045,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}